IP Library Granted Patent US 7,122,357
Granted Patent B2
US 7,122,357 · App. 09/953,450 · Granted Oct 17, 2006

Method for the treatment of diabetes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,122,357
App. No.
09/953,450
Granted
Oct 17, 2006
Kind
B2
Abstract

The use of physiologically acceptable enzyme mixtures having lipolytic, proteolytica and amylolytic activity, of microbial or animal origin, preferably digestive enzyme mixtures such as pancreatin or digestive enzyme mixtures containing pancreatin, for the treatment of diabetes. The invention also relates to the production of pharmaceutical compositions suitable for such treatment. A preferred variant of the invention relates to use of this enzyme mixture having lipolytic, proteolytic and amylolytic activity, especially digestive enzyme mixtures such as pancreatin or digestive enzyme mixtures containing pancreatin, for the adjuvant treatment of type I or type II diabetes mellitus.

Claims (7)

1. A method of treating a larger mammal or human suffering from primary diabetes mellitus Type I comprising administering to said mammal or human an effective amount of a pharmaceutical preparation comprising a physiologically acceptable enzyme mixture having lipolytic, proteolytic and amylolytic activity.

2. A method according to claim 1 , wherein said pharmaceutical preparation comprises a physiologically acceptable enzyme mixture of microbially synthesized lipases, proteases and amylases.

3. A method according to claim 1 , wherein said pharmaceutical preparation comprises pancreatin.

4. A method according to claim 1 , wherein said pharmaceutical preparation comprises a mixture of digestive enzymes containing pancreatin.

5. A method according to claim 3 , wherein said pharmaceutical preparation comprises pancreatin or a mixture of digestive enzymes containing pancreatin, and at least one microbial enzyme selected from the group consisting of lipases, proteases and amylases.

6. A method according to claim 1 , wherein said pharmaceutical preparation is administered as an adjuvant therapy in conjunction with another, primary therapy.

7. A method according to claim 1 , wherein said larger mammal or human is a patient suffering from diabetes mellitus accompanied by exocrine pancreatic insufficiency.

Assignments (2)
CHANGE OF NAME Recorded Jun 21, 2012
From: SOLVAY PHARMACEUTICALS GMBH
To: ABBOTT PRODUCTS GMBH
Reel/Frame 028416/0018 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2001
From: SANDER-STRUCKMEIER, SUNTJE; STEINBORN, CLAUS RUDOLF; RUDMANN, MARTIN A.; SCHWANITZ, DIETHARD; HENNIGES, FRIEDERIKE
To: SOLVAY PHARMACEUTICALS GMBH
Reel/Frame 012363/0071 →